Renin inhibitors: Optimal strategy for renal protection

Current Hypertension Reports

Volumn 9, Issue 5, 2007, Pages 415-421

  Schmieder, Roland E ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALISKIREN; AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALKIREN; IRBESARTAN; KIDNEY RENIN; LISINOPRIL; LOSARTAN; PLACEBO; REMIKIREN; RENIN INHIBITOR; TRANDOLAPRIL; VALSARTAN;

BLOOD PRESSURE REGULATION; CHRONIC KIDNEY DISEASE; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE COURSE; DRUG DOSAGE FORM COMPARISON; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; ENZYME ANALYSIS; ENZYME INHIBITION; HEMODIALYSIS; HUMAN; HYPERTENSION; KIDNEY BLOOD FLOW; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; MONOTHERAPY; NONHUMAN; PATHOPHYSIOLOGY; PLASMA RENIN ACTIVITY; RECEPTOR BLOCKING; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VASOCONSTRICTION; WATER RETENTION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; CLINICAL TRIALS AS TOPIC; DIABETIC NEPHROPATHIES; HUMANS; HYPERTENSION; KIDNEY FAILURE, CHRONIC; RATS; RENIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 36849037315     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-007-0076-5     Document Type: Review

References (55)

1. National Kidney Foundation: Kidney disease. Available at: http://www.kidney.org/kidneyDisease/. Accessed November 16, 2006.
2. US Renal Data System: USRDS 2006 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2006.
3. Chobanian AV, Bakris GL, Black HR, et al.: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003, 289:2560-2572.
4. Neal B, MacMahon S, Chapman N, et al.: Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet 2000, 356:1955-1964.
5. Strippoli GF, Bonifati C, Craig M, et al.: Angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease. Cochrane Database Syst Rev 2006, (4):CD006257.
6. Carey RM, Siragy HM: Newly recognized components of the renin-angiotensin system: potential roles in cardiovascular and renal regulation. Endocr Rev 2003, 24:261-271.
7. Kaschina E, Unger T: Angiotensin AT1/AT2 receptors: regulation, signalling and function. Blood Press 2003, 12:70-88.
8. Brewster UC, Setaro JF, Perazella MA: The renin-angiotensin-aldosterone system: cardiorenal effects and implications for renal and cardiovascular disease states. Am J Med Sci 2003, 326:15-24.
9. Cooper ME: The role of the renin-angiotensin-aldosterone system in diabetes and its vascular complications. Am J Hypertens 2004, 17:16S-20S.
10. Hilgers KF, Mann JF: ACE inhibitors versus AT(1) receptor antagonists in patients with chronic renal disease. J Am Soc Nephrol 2002, 13:1100-1108.
11. Schmieder RE: Mechanisms for the clinical benefits of angiotensin II receptor blockers. Am J Hypertens 2005, 18:720-730.
12. Mezzano S, Droguett A, Burgos ME, et al.: Renin-angiotensin system activation and interstitial inflammation in human diabetic nephropathy. Kidney Int Suppl 2003, 86:S64-70.
13. Navar LG, Harrison-Bernard LM, Nishiyama A, Kobori H: Regulation of intrarenal angiotensin II in hypertension. Hypertension 2002, 39:316-322.
14. Hollenberg NK, Price DA, Fisher ND, et al.: Glomerular hemodynamics and the renin-angiotensin system in patients with type 1 diabetes mellitus. Kidney Int 2003, 63:172-178.
15. Schmieder RE, Hilgers KF, Schlaich MP, Schmidt BMW: The renin angiotensin system and cardiovascular risk. Lancet 2007, 369:1208-1219.
16. Wolf G: Angiotensin II is involved in the progression of renal disease: importance of non-hemodynamic mechanisms. Nephrologie 1998, 19:451-456.
17. Schmieder RE: The potential role of prorenin in diabetic nephropathy. J Hypertens 2067, 25:1323-1326.
18. Reudelhuber TL: The continuing saga of the AT2 receptor: a case of the good, the bad, and the innocuous. Hypertension 2005, 46:1261-1262.
19. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia): Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997, 349:1857-1863.
20. Brenner BM, Cooper ME, de Zeeuw D, et al.: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861-869.
21. Lewis EJ, Hunsicker LG, Clarke WR, et al.: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001, 345:851-860.
22. Pohl MA, Blumenthal S, Cordonnier DJ, et al.: Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations. J Am Soc Nephrol 2005, 16:3027-3037.
23. Weber MA, Giles TD: Inhibiting the renin-angiotensin system to prevent cardiovascular diseases: do we need a more comprehensive strategy? Rev Cardiovasc Med 2006, 7:45-54.
24. Rossing K, Schjoedt KJ, Jensen BR, et al.: Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria. Kidney Int 2005, 68:1190-1198.
25. Nakao N, Yoshimura A, Morita H, et al.: Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003, 361:117-124,
26. Mogensen CE, Neldam S, Tikkanen I, et al.: Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000, 321:1440-1444.
27. Schmieder RE, Klingbeil AU, Fleischmann EH, et al.: Additional antiproteinuric effect of ultrahigh-dose candesartan: a double-blind, randomized, prospective study. J Am Soc Nephrol 2005, 16:3038-3045.
28. Stanton A: Therapeutic potential of renin inhibitors in the management of cardiovascular disorders. Am J Cardiovasc Drugs 2003, 3:389-394.
29. Wood JM, Maibaum J, Rahuel J, et al.: Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem Biophys Res Commun 2003, 308:698-705.
30. Pool J, Gradman A, Kolloch R, et al.: Aliskiren, a novel renin inhibitor, provides long-term suppression of the renin system, when used alone or in combination with hydrochlorothiazide in the treatment of hypertension. Eur Heart J 2006, 27:119.
31. Kilo C, Taylor A, Tschoepe D, et al.: Aliskiren, a novel renin inhibitor for treatment of hypertension, enhances renin system suppression by reducing plasma renin activity alone or in combination with ramipril in patients with diabetes. Eur Heart J 2006, 27:118-119.
32. Azizi M, Menard J, Bissery A, et al.: Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. J Am Soc Nephrol 2004, 15:3126-3133.
33. Nguyen G, Delarue F, Burckle C, et al.: Pivotal role of the renin/ prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest 2002, 109:1417-1427.
34. Azizi M, Webb R, Nussberger J, Hollenberg NK: Renin inhibition with aliskiren: where are we now, and where are we going? J Hypertens 2006, 24:243-256.
35. Webb DJ, Manhem PJ, Bali SG, et al.: Clinical and biochemical effects of the renin inhibitor H142 in humans. J Cardiovasc Pharmacol 1987, 10:S69-74.
36. Zusman RM, Hui KY, Nussberger J, et al.: R-PEP-27, a potent renin inhibitor, decreases plasma angiotensin II and blood pressure in normal volunteers. Am J Hypertens 1994, 7:295-301.
37. Menard J, Boger RS, Moyse DM, et al.: Dose-dependent effects of the renin inhibitor zankiren HCI after a single oral dose in mildly sodium-depleted normotensive subjects. Circulation 1995, 91:330-338.
38. Azizi M, Guyene TT, Chatellier G, Menard J: Blood pressure effects of acute intravenous renin or oral angiotensin converting enzyme inhibition in essential hypertension. J Hypertens 1994, 12:419-427.
39. Neutel JM, Luther RR, Boger RS, Weber MA: Immediate blood pressure effects of the renin inhibitor enalkiren and the angiotensin-converting enzyme inhibitor enalaprilat. Am Heart J 1991, 122:1094-1100.
40. Oh B-H, Chung J, Khan M, et al.: Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and placebo-like tolerability in patients with hypertension. J Am Coll Cardiol 2006, 47:370A.
41. Gradman AH, Schmieder RE, Lins RL, et al.: Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation 2005, 111:1012-1018.
42. Weir MR, Bush C, Zhang J, et al.: Antihypertensive efficacy and safety of the oral renin inhibitor aliskiren in patients with hypertension: a pooled analysis. Eur Heart J 2006, 27:299.
43. Strasser RH, Puig JG, Farsang C, et al.: The oral renin inhibitor aliskiren has comparable safety and efficacy to lisinopril in patients with severe hypertension. J Hypertens 2006, 24:99-100.
44. Uresin Y, Taylor A, Kilo C, et al.: Aliskiren, a novel renin inhibitor, has greater BP lowering than ramipril and additional BP lowering when combined with ramipril in patients with diabetes and hypertension. J Hypertens 2006, 24:S82.
45. Villamil A, Chrysant S, Calhoun D, et al.: The novel oral renin inhibitor aliskiren provides effective blood pressure control in patients with hypertension when used alone or in combination with hydrochlorothiazide. J Clin Hypertens 2006, 8:A100.
46. Munger MA, Drummond W, Essop MR, et al.: Aliskiren as add-on to amlodipine provides significant additional blood pressure lowering without increased oedema associated with doubling the amlodipine dose. Eur Heart J 2006, 27:117.
47. Mitchell J, Oh B, Herron J, et al.: Once-daily aliskiren provides effective, smooth 24-hour blood pressure control in patients with hypertension. J Clin Hypertens 2006, 8:A93.
48. Herron J, Mitchell J, Oh B, et al.: The novel renin inhibitor aliskiren is not associated with rebound effects on blood pressure or plasma renin activity following treatment withdrawal. J Clin Hypertens 2006, 8:A86-87.
49. Sica D, Gradman A, Lederballe O, et al.: Aliskiren, a novel renin inhibitor, is well tolerated and has sustained BP-lowering effects alone or in combination with HCTZ during long-term (52 weeks) treatment of hypertension. Eur Heart J 2006, 27:121.
50. Fisher ND, Hollenberg N: Renal vascular responses to renin inhibition with zankiren in men. Clin Pharmacol Ther 1995, 57:342-348.
51. van Paassen P, de Zeeuw D, Navis G, de Jong PE: Renal and systemic effects of continued treatment with renin inhibitor remikiren in hypertensive patients with normal and impaired renal function. Nephrol Dial Transplant 2000, 15:637-643.
52. Pilz B, Shagdarsuren E, Wellner M, et al.: Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats. Hypertension 2005, 46:569-576.
53. Fiebeler A, Shagdarsuren E, Pilz B, et al.: Low-dose renin inhibitor and AT1 receptor blocker ameliorate angiotensin II-induced end-organ damage despite persistence of hypertension. Results presented at Renal Week. Philadelphia, PA; November 8-13, 2005.
54. Feldman DL, Jin L, Miserindino-Moltini R, et al.: Aliskiren, a human renin inhibitor induces persistent renoprotection comparable to ACE inhibition in double transgenic rats (dTGR). Am J Hypertens 2005, 8:230A.
55. Feldman DL, Jin L, Miserindino-Moltini R, et al.: The renin inhibitor aliskiren ameliorates hypertensive diabetic nephropathy in transgenic (nRen-2)27 (Ren-2) rats. Results presented at Renal Week. Philadelphia, PA; November 8-13, 2005.